

Francesca Cossarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6603487/publications.pdf>

Version: 2024-02-01

29
papers

2,144
citations

759233

12
h-index

580821

25
g-index

31
all docs

31
docs citations

31
times ranked

6624
citing authors

#	ARTICLE	IF	CITATIONS
1	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. <i>Nature Medicine</i> , 2022, 28, 766-779.	30.7	70
2	785 SARS-COV-2 INFECTS ENTEROCYTES IN VIVO AND CAN PERSIST UP TO 7 MONTHS FOLLOWING RESOLUTION OF SYMPTOMS. <i>Gastroenterology</i> , 2021, 160, S-159.	1.3	1
3	Fr137 FIRST HIGH DIMENSIONAL EXAMINATION OF INTESTINAL BIOPSIES IN PATIENTS WITH COVID-19. <i>Gastroenterology</i> , 2021, 160, S-234-S-235.	1.3	0
4	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. <i>Gastroenterology</i> , 2021, 160, S-330.	1.3	0
5	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	1.3	118
6	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. <i>Scientific Reports</i> , 2021, 11, 13308.	3.3	50
7	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	14.3	1,387
8	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. <i>Clinical Infectious Diseases</i> , 2020, 71, 2933-2938.	5.8	189
9	Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare. <i>AIDS and Behavior</i> , 2018, 22, 3519-3524.	2.7	7
10	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2017, 17, 43.	2.9	15
11	Characteristics of Patients Who Acquired Human Immunodeficiency Virus (HIV) Infection Despite Accessing Healthcare: Implications for HIV Prevention Strategies. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
12	Immortal time bias. <i>Aids</i> , 2015, 29, 860-861.	2.2	1
13	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. <i>Aids</i> , 2015, 29, 857-859.	2.2	0
14	Ranolazine-induced Repolarization Changes: A Case Report. <i>American Journal of Medicine</i> , 2015, 128, e3-e5.	1.5	5
15	The Reply. <i>American Journal of Medicine</i> , 2015, 128, e39.	1.5	4
16	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , 2014, 28, 2407-2415.	2.2	16
17	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-infected patients. <i>Cancer</i> , 2013, 119, 2710-2719.	4.1	3
18	Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy. <i>Antiviral Therapy</i> , 2012, 17, 447-458.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Immune recovery and T cell subset analysis during effective treatment with maraviroc. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2474-2478.	3.0	10
20	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 213-217.	3.0	26
21	Monotherapy With Atazanavir as a Simplificati Strategy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e101-e103.	2.1	4
22	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. <i>Aids</i> , 2012, 26, 1837-1840.	2.2	11
23	Tenâ€year survival among HIVâ€infected subjects with AIDS or nonâ€AIDSâ€defining malignancies. <i>International Journal of Cancer</i> , 2012, 130, 2990-2996.	5.1	29
24	Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e113-e115.	2.1	19
25	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With Lamivudine-Resistant HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e34-e35.	2.1	1
26	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. <i>Journal of Infectious Diseases</i> , 2011, 204, 1811-1815.	4.0	94
27	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e51-e53.	2.1	14
28	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	3.1	4
29	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 179-184.	2.1	4